Astellas and seagen announce positive topline results for padcev® (enfortumab vedotin-ejfv) with keytruda® (pembrolizumab) as first-line treatment for advanced urothelial cancer

– companies plan to discuss results with regulatory authorities – tokyo and bothell, wash. , july 26, 2022 /prnewswire/ -- astellas pharma inc. (tse:4503, president and ceo: kenji yasukawa, ph.d.

SGEN Ratings Summary

SGEN Quant Ranking